Literature DB >> 2295442

Endometrial stromal sarcomas.

J L Mansi1, S Ramachandra, E Wiltshaw, C Fisher.   

Abstract

The case histories of 15 patients with endometrial stromal sarcoma attending the Royal Marsden Hospital between 1973 and 1987 were reviewed. Eight patients were classified as having low-grade and seven as high-grade tumors using specific histological criteria. Those patients with low-grade tumors had a long relapse-free and overall survival in the absence of receiving specific therapy after initial surgery. Five are alive and disease free, one has shown a partial response to hormonal manipulation, and one is alive with disease on no therapy. Only one patient has died and this occurred 111 months postdiagnosis. Conversely, all seven patients with high-grade tumors relapsed with local disease and three have died. Thus, after surgical resection patients with low-grade tumors probably do not require treatment until relapse, whereas adjuvant radiotherapy should be given to those patients with high-grade tumors. On relapse, hormone therapy should be the treatment of first choice for patients with low-grade tumors, whereas chemotherapy is more appropriate for patients with high-grade tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295442     DOI: 10.1016/0090-8258(90)90120-a

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Metastatic low-grade endometrial stromal sarcoma of the sigmoid colon three years after hysterectomy.

Authors:  Yuki Asada; Hajime Isomoto; Fumitaka Akama; Noriko Nomura; Chun-Yang Wen; Haruhiko Nakao; Ikuo Murata; Kan Toriyama; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 2.  JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas: molecular analysis by reverse transcriptase-polymerase chain reaction optimized for paraffin-embedded tissue.

Authors:  Andelko Hrzenjak; Farid Moinfar; Fattaneh A Tavassoli; Bettina Strohmeier; Marie-Luise Kremser; Kurt Zatloukal; Helmut Denk
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

3.  Endometrial stromal sarcoma. Is there a place for radiotherapy?

Authors:  Izaskun Valduvieco; Angeles Rovirosa; Lluis Colomo; Alex De San Juan; Jaume Pahisa; Albert Biete
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

Review 4.  Current management of uterine sarcomas.

Authors:  Elena García-Martínez; Lucas Egea Prefasi; Jesús García-Donas; Pedro Pablo Escolar-Pérez; Francisco Pastor; Antonio González-Martín
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

5.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

6.  Proliferating cell nuclear antigen and S phase fraction in endometrial stromal sarcoma.

Authors:  J B Schofield; J Mansi; R S Camplejohn; D P Lane; C Fisher
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

7.  Recurrent endometrial stromal sarcoma: treatment with a progestin and gonadotropin releasing hormone agonist.

Authors:  Nefertiti Chianti Dupont; Philip John Disaia
Journal:  Sarcoma       Date:  2010-06-10

8.  Endometrial stromal sarcomas: a retrospective analysis of 28 patients, single center experience for 20 years.

Authors:  Eun Ji Nam; Jae Wook Kim; Dae Woo Lee; Si Young Jang; Jong Wook Hong; Young Tae Kim; Jae Hoon Kim; Sunghoon Kim; Sang Wun Kim
Journal:  Cancer Res Treat       Date:  2008-03-31       Impact factor: 4.679

9.  Endometrial stromal sarcoma metastasis to the lumbar spine and sphenoid bone.

Authors:  Mary I Huang; Robert L Debernardo; Mark Rodgers; David J Hart
Journal:  Rare Tumors       Date:  2011-10-21

10.  Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study.

Authors:  Hiroyuki Yamazaki; Yukiharu Todo; Kenrokuro Mitsube; Hitoshi Hareyama; Chisa Shimada; Hidenori Kato; Katsushige Yamashiro
Journal:  J Gynecol Oncol       Date:  2015-04-16       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.